Recursion Pharmaceuticals, Inc. (RXRX)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS75629V1044
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Recursion Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:36. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -0.20 | — | — | Upcoming |
| 02 Nov 2026 16:00 | -0.23 | -0.22 | +3.9% | Beat |
| 05 Aug 2026 06:00 | -0.23 | -0.25 | -6.8% | Miss |
| 06 May 2026 06:00 | -0.26 | -0.22 | +14.4% | Beat |
| 25 Feb 2026 06:00 | -0.32 | -0.21 | +33.3% | Beat |
| 05 Nov 2025 06:00 | -0.38 | -0.36 | +5.7% | Beat |
| 05 Aug 2025 06:00 | -0.35 | -0.41 | -16.0% | Miss |
| 05 May 2025 06:00 | -0.52 | -0.50 | +3.1% | Beat |
| 28 Feb 2025 06:00 | -0.42 | -0.53 | -27.2% | Miss |
| 06 Nov 2024 16:00 | -0.33 | -0.34 | -2.2% | Miss |
| 08 Aug 2024 07:00 | -0.38 | -0.40 | -4.2% | Miss |
| 09 May 2024 16:00 | -0.43 | -0.39 | +8.6% | Beat |
| 27 Feb 2024 16:00 | -0.45 | -0.42 | +6.4% | Beat |
| 09 Nov 2023 07:00 | -0.39 | -0.43 | -11.6% | Miss |
| 08 Aug 2023 07:00 | -0.37 | -0.38 | -1.3% | Miss |
| 08 May 2023 08:00 | -0.35 | -0.34 | +3.0% | Beat |
| 27 Feb 2023 16:00 | -0.24 | -0.30 | -26.8% | Miss |
| 08 Nov 2022 16:00 | -0.38 | -0.35 | +7.6% | Beat |
| 09 Aug 2022 16:00 | -0.37 | -0.38 | -1.8% | Miss |
| 10 May 2022 16:00 | 0.51 | -0.33 | -164.7% | Miss |
| 23 Mar 2022 07:00 | -0.31 | -0.38 | -23.6% | Miss |
| 10 Nov 2021 07:00 | -0.28 | -0.28 | +0.2% | In line |
| 13 Aug 2021 07:00 | -0.24 | -0.31 | -28.6% | Miss |
| 12 May 2021 08:00 | -0.23 | -0.23 | +1.0% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 74.3M | +27.0% | -644.8M | -868.3% | -1.44 | +14.8% | -380.4M |
| 2024 | 58.5M | +33.3% | -463.7M | -792.7% | -1.69 | -7.0% | -376.2M |
| 2023 | 43.9M | +10.6% | -328.1M | -747.7% | -1.58 | -16.2% | -300.3M |
| 2022 | 39.7M | — | -239.5M | -603.5% | -1.36 | — | -120.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 4.11 | 4.17 | 3.22 | 3.22 | -20.08% | 185,204,837 | |
| Oct 2026 | 4.07 | 5.19 | 3.44 | 4.03 | -2.42% | 667,019,400 | |
| Sep 2026 | 3.34 | 4.29 | 3.10 | 4.13 | +21.47% | 430,132,500 | |
| Aug 2026 | 3.03 | 3.63 | 2.92 | 3.40 | +13.33% | 322,294,900 | |
| Jul 2026 | 3.65 | 4.09 | 2.84 | 3.00 | -18.26% | 506,268,100 | |
| Jun 2026 | 3.53 | 4.04 | 2.95 | 3.67 | +2.23% | 452,963,000 | |
| May 2026 | 3.46 | 3.68 | 2.77 | 3.59 | +3.76% | 340,551,800 | |
| Apr 2026 | 3.13 | 3.90 | 2.93 | 3.46 | +12.70% | 231,422,600 | |
| Mar 2026 | 3.48 | 3.76 | 2.80 | 3.07 | -16.35% | 310,291,600 | |
| Feb 2026 | 4.12 | 4.29 | 2.98 | 3.67 | -12.41% | 430,879,500 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (opens in a new tab) MarketBeat · 11 Nov 2026 13:10
- Recursion to Participate in Upcoming Investor Conferences (opens in a new tab) 11 Nov 2026 13:00
- Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data, Early ... (opens in a new tab) GuruFocus.com · 11 Nov 2026 01:07
- AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing (opens in a new tab) 09 Nov 2026 15:14
- Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates? (opens in a new tab) Simply Wall St. · 05 Nov 2026 08:16
- REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock (opens in a new tab) Simply Wall St. · 05 Nov 2026 00:15
- Recursion Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 00:14
- Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 Win (opens in a new tab) Simply Wall St. · 04 Nov 2026 22:15
- RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway (opens in a new tab) Zacks · 04 Nov 2026 14:00
- Recursion Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 22:08
- Recursion (RXRX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 20:47
- What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 03 Nov 2026 19:14
- Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues (opens in a new tab) Zacks · 03 Nov 2026 14:59
- Recursion Pharmaceuticals: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 03 Nov 2026 04:37
- Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates (opens in a new tab) Zacks · 02 Nov 2026 23:10
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 3.33 USD
- Market cap
- 2.1B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow RXRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.